Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
Status:
Withdrawn
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an
effective and safe treatment for cancer subjects with metastatic uveal melanoma and
mutation-positive GNAQ or GNA11 metastatic melanoma.